144457-28-3

Basic information

• Product Name: CLOPIDOGREL CARBOXYLIC ACID
• Synonyms: (S)-α-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic Acid;SR 26334;(S)-2-(2-Chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetic acid;(S)-Clopidogrel Carboxylic Acid (Clopidogrel Related CoMpound A);Clopidogrel Carboxylic Acid Discontinued See C587235;Clopidogrel Related Compound A ((S)-Clopidogrel Carboxylic Acid);(S)-Clopidogrel Carboxylic Acid
• CAS NO: 144457-28-3
• Molecular Formula: C₁₅H₁₄ClNO₂S
• Molecular Weight: 307.8
• Product Categories: Various Metabolites and Impurities;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Aromatics;Heterocycles;Sulfur & Selenium Compounds
• Mol File: 144457-28-3.mol
• Article Data: 13

Chemical Properties

• Melting Point: 139-141°C
• Boiling Point: 447.3°C at 760 mmHg
• Flash Point: 224.3°C
• Appearance: Light-tan solid
• Density: 1.405g/cm³
• Vapor Pressure: 8.71E-09mmHg at 25°C
• Refractive Index: 1.658
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• PKA: 1.61±0.10(Predicted)
• CAS DataBase Reference: CLOPIDOGREL CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: CLOPIDOGREL CARBOXYLIC ACID(144457-28-3)
• EPA Substance Registry System: CLOPIDOGREL CARBOXYLIC ACID(144457-28-3)

Safety Data

• Hazardous Substances Data: 144457-28-3(Hazardous Substances Data)

Usage

Chemical Properties

Light-Tan Solid

Uses

A metabolite of the drug Clopidogrel

InChI:InChI=1/C15H14ClNO2S/c16-12-4-2-1-3-11(12)14(15(18)19)17-7-5-13-10(9-17)6-8-20-13/h1-4,6,8,14H,5,7,9H2,(H,18,19)

Upstream product

• 1015247-90-1 (+)-((2-chlorophenyl)-6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetic acid (1R)-(-)-camphor-10-sulfonate 
• 50-00-0 formaldehyd 
• 141315-50-6 (S)-2-amino-(2-chlorophenyl)ethanoic acid 
• 917613-68-4 (S)-(+)-α-(2-chlorophenyl)-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-acetic acid, (1R,2R)-(-)-2-amino-1-(4-nitrophenyl)-1,3-propanediol salt 
• 1007128-30-4 C₁₅H₁₄ClNO₂S*C₁₉H₂₂N₂O 
• 120202-66-6 (S)-(+)-clopidogrel bisulfate 
• 113665-84-2 (S)-(+)-clopidogrel 
• 444891-19-4 2-bromo-2-(2-chlorophenyl)acetonitrile 
• 444728-11-4 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)acetonitrile 
• 90055-55-3 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)acetic acid 
• 90055-48-4 clopidogrel 
• 2856-63-5 2-Chlorophenylacetonitrile 

Downstream Products

• 113665-84-2 (S)-(+)-clopidogrel 
• 144750-42-5 (S)-(+)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno-[3,2-c]pyridin-5(4H)-yl)acetic acid hydrochloride 
• 917613-71-9 C₁₅H₁₃Cl₂NOS 

Relevant articles and documents

Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver

The aim of this study was to conclusively determine the enzyme responsible for the hydrolysis of oxybutynin in human liver. Hydrolysis in human liver microsomes (HLMs) and human liver cytosol (HLC) followed Michaelis-Menten kinetics with similar Km values. In recombinant human carboxylesterase (CES)-expressing microsomes, CES1 was much more efficient than CES2 and yielded a Km value more comparable with that found in HLMs or HLC than did CES2. A correlation analysis using a set of individual HLMs, in which both CESs acted independently showed that the hydrolysis rate of oxybutynin, correlated significantly with a CES1 marker reaction, clopidogrel hydrolysis, but not with a CES2 marker reaction, irinotecan (CPT-11) hydrolysis. Chemical inhibition studies using bis-(p-nitrophenyl) phosphate, clopidogrel, nordihydroguaiaretic acid, procainamide, physostigmine, and loperamide revealed that the effects of these compounds in HLMs, HLC, and recombinant CES1-expressing microsomes were similar, whereas those in CES2-expressing microsomes were clearly different. These results strongly suggest that CES1, rather than CES2, is the principal enzyme responsible for the hydrolysis of oxybutynin in human liver. Copyright

Ginkgolide B Derivative and Preparation Method And Use Thereof

Disclosed are a compound as shown in formula I or formula II or a pharmaceutically acceptable salt thereof, wherein R1 is selected from pyrazinyl or substituted pyrazinyl; and R2 is selected from pyrazinyl or substituted pyrazinyl, phenyl or substituted phenyl, alkyl or substituted alkyl.

Prodrugs of anti-platelet agents

The invention relates to the compounds of formula I, formula II, formula Ia, formula IIb or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula Ia, formula IIb and methods for treating or preventing atherothrombosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.